Targovax - Småprat 2 (TRVX) 1

[solvoll]

Og/eller radium podcast i morgen

[Morgo26]

Of course. Forgot about that. Fingers crossed we get some tidbits of info there.

[Guny]

Jeg føler de må levere mer en ok resultater i melanom. Markedet reagerer ikke på ok! Nå håper jeg at guidingen på melanom blir som lovet, og ORR er på minimum 5 av 12. Og at kina avtalen slår inn!

[Aksjer888]

Hva er den høyeste aksjekursen dere tør håpe på før jul?

[Guny]

Hvis det slår inn det jeg skrev ovenfor, så håper jeg på en dobling. Men jeg har vært i denne aksjen i 4 år, ingenting overrasker meg lenger.

[Bianchi]

Jeg personlig håper Aborum får rett og at vi hilser på 20.00😊

[anon80503862]

Har ingen forhåpninger før jeg ser melanomdata.

[Frs2904]

Alt vil stå og falle på videre finansiering. Hvis de skal basere seg på flere emisjoner tipper jeg kursen blir liggende i gjørma lenge. Overrasker de med avtaler som genererer penger i kassa, så vil nok kursen gå bananas. Dessverre får de ikke utrettet så mye annet enn å holde liv i selskapet noen måneder med de millionene som de hentet fra emisjonen som var. Hvem av de store aktørene som har deltatt i de 3 siste emisjonene er fortsatt med??? Største aksjonær har jo ikke deltatt om de ikke leverer i morgen er jeg redd vi nærmer oss 5-tallet og hvem hadde trodd det for noen uker side da vi var i full fart mot 10-tallet.

[Guny]

De sier de har det beste viruset, nå må det vises, så vi alle forstår det🥳 Hvis finansiering av videre studier blir et problem, da skal jeg ut så fort som mulig. Ut i fra de seneste presentasjonene til Targo, så har jeg et håp om at noe skjer🚀

[Investor6]

slettet

[Whatsthat]

Replimune (0/16), checkmate (2/83) og syndax (1/53) har tilsammen rapportert totalt 3 CR på 152 pasienter…

Targovax har til nå i 1 CR (nesten 2) av 9 på det PI og CMO tror er feil eller for lav dose (cohort1).

En bekreftelse av CR ratio og økt ORR med “riktig” dosering er ønskelig utfall.

Kanskje kjøpt opp hvis de får 3/12 CR i cohort 2? 3 av 12 er da noe bedre enn 3 av 152

[Ramsess]

Meanwhile:

[gummihansken]

Sykt 9.32 mrd usd

[Ramsess]

Ja, I blame the backwards hillbilly in the middle of nowhere OBX…

[Helt1]

1 CR til er vel nok til å få opp øynene på flere,

[Ramsess]

Jeg satser på at Vaccibody kan åpne veien for norske biotek i utlandet.

[BioMed]

Most recently, Targovax developed TG01, a peptide cocktail
vaccine that targets 7 peptides mutated in most PDAC tumors, including mutant ras. The phase
I trial demonstrated delayed-type hypersensitivity immune response in 100% of patients (n = 6).
Currently, TG01 is being tested in combination with GM-CSF and gemcitabine in a phase II clinical
trial (NCT02261714). KRAS remains an oncogenic target of interest.

biomedicines-08-00401-v2.pdf (2,9 MB)

[TekBot]

Targovax announces formation of new Scientific Advisory Board

Oslo, Norway, 28 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage
immuno-oncology company developing oncolytic viruses to target hard-to-treat
solid tumors, today announces the formation of a new Scientific Advisory Board
…

Vis børsmeldingen

(SAB). The SAB consists of a group of world-renowned experts in immuno-oncology
research and drug development carefully selected to act as advisors to guide the
Targovax R&D strategy.

Victor Levitsky, Chief Scientific Officer of Targovax said: We are very pleased
to have attracted such high caliber individuals with deep expertise in immuno
-oncology to serve on the newly formed Targovax Scientific Advisory Board. In
their capacity as world-leading experts in immuno-oncology drug development,
oncolytic viruses and mesothelioma, Dr. Clynes, Dr. Zamarin and Prof. Fennel
cover the key scientific focus areas of Targovax. We are confident that the
discussions with the advisory board will be very insightful and instrumental as
we develop and implement the next phase of the Targovax R&D strategy".

The SAB will be comprised of the following members:

· Raphael Clynes, MD, PhD: Dr. Clynes is an MIT graduate, MD/PhD immunologist,
and MSKCC-trained hematologist/oncologist. As a well-recognized expert in
clinical immunology, he has extensive prior experience as a contributing member
of multiple SABs in biopharma and review boards at the NIH and national research
foundations. In his academic career, Dr. Clynes established the critical role of
Fc receptor engagement underlying the efficacy of antitumor antibodies,
providing the road map for the development of a new class of potency enhanced Fc
engineered antibodies in cancer, including anti-CD20, anti-CD19 and anti-HER2
antibodies (obinutuzumab, tafacitamab, margetuximab). At Columbia, Dr. Clynes
developed several novel therapeutic approaches in cancer and autoimmunity,
including DC targeting for cancer vaccines and Syk and JAK mediated inhibition
of DCs and T cells in autoimmunity therapy. Since 2014, Dr. Clynes has led
clinical development of checkpoint, CD3 bi-specifics and cytokine programs in
immunotherapy at Bristol Myers Squibb and at Xencor, where he is currently VP
Translational Biology and oversees seven immunotherapeutic assets currently in
clinical development for cancer and autoimmunity.

· Dmitriy Zamarin, MD, PhD: Dr. Zamarin is an Assistant Attending Physician
and Translational Research Director in the Gynecologic Medical Oncology Service
at the Memorial Sloan Kettering Cancer Center. He is also a principal
investigator and a translational chair on several institutional and cooperative
group clinical trials exploring novel immunotherapy combinations in gynecologic
cancers and other solid tumors. Dr. Zamarin’s clinical and laboratory research
are focused on characterization of biomarkers in patients undergoing
immunotherapy and on development of novel immunotherapeutic strategies using
immunomodulatory antibodies and genetically-engineered oncolytic viruses.
Specifically, by manipulating the oncolytic viruses and the immune system, he is
exploring different ways to enhance the immune recognition of tumors and to
develop novel treatment strategies that could overcome resistance to immune
checkpoint blockade.

· Dean A. Fennell, FRCP, PhD: Professor Fennell is Professor & consultant in
Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Program
based at the University of Leicester/University Hospitals of Leicester NHS
Trust. He is an internationally recognized key opinion leader, clinical
investigator and translational research in mesothelioma. He has led several
investigator-initiated trials from phase 1 through phase III. Prof. Fennell is
member of the IASLC mesothelioma taskforce, steering committee for the British
Lung Foundation mesothelioma research network, past president of the
International mesothelioma interest group, co-author of the UK BTS, and European
(ESMO, ERS) mesothelioma treatment guidelines and served two terms on the EORTC
board. He is currently the Leicester lead for the groundbreaking Cancer Research
UK TraceRx/Darwin/PEACE and BLF supported MEDUSA phylogenetic studies. Prof.
Fennell has published over 100 peer reviewed articles in journals including The
Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature Reviews
Cancer, and Proceedings of the National Academy of Sciences.

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
oncolytic viruses to target hard-to-treat solid tumors. Targovax’s lead product
candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has
been engineered to selectively infect cancer cells and activate the immune
system to fight the cancer.

ONCOS-102 is currently being tested in mesothelioma, melanoma and peritoneal
malignancies and has already shown promising clinical results both as
monotherapy and in combination with chemotherapy, and a checkpoint inhibitor.

Kilde

[Andre10k]

· Dean A. Fennell, FRCP, PhD: Professor Fennell is Professor & consultant in
Thoracic Medical Oncology, and Director of the Leicester Mesothelioma Program
based at the University of Leicester/University Hospitals of Leicester NHS
Trust. He is an internationally recognized key opinion leader, clinical
investigator and translational research in mesothelioma. He has led several
investigator-initiated trials from phase 1 through phase III. Prof. Fennell is
member of the IASLC mesothelioma taskforce, steering committee for the British
Lung Foundation mesothelioma research network, past president of the
International mesothelioma interest group, co-author of the UK BTS, and European
(ESMO, ERS) mesothelioma treatment guidelines and served two terms on the EORTC
board. He is currently the Leicester lead for the groundbreaking Cancer Research
UK TraceRx/Darwin/PEACE and BLF supported MEDUSA phylogenetic studies. Prof.
Fennell has published over 100 peer reviewed articles in journals including The
Lancet, Lancet Oncology, New England Journal of Medicine, Nature, Nature Reviews
Cancer, and Proceedings of the National Academy of Sciences.

Fin resymé må jeg si. Skader vel ikke med litt ekspertise inputs

[TheObserver]

Fritt fra husken; var det ikke dr Zamarin som sa at Oncos 102 var bedre innen Melanom enn SoC i forbindelse med en konferanse hvor man gikk gjennom dataene fra første cohort?

Ingen forsamling med lettvektere dette nei

(Husken var nok feil, her er han jeg tenkte på;
Dr. Shoushtari, MD, Medical Oncologist, Memorial Sloan Kettering, presented results from part 1 of Targovax’s phase I trial in anti-PD1 refractory melanoma combining ONCOS-102 with Keytruda. )